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Abstract
Background: Chromosomal breakage followed by faulty DNA repair leads to gene amplifications and deletions in
cancers. However, the mere assessment of the extent of genomic changes, amplifications and deletions may
reduce the complexity of genomic data observed by array comparative genomic hybridization (array CGH). We
present here a novel approach to array CGH data analysis, which focuses on putative breakpoints responsible for
rearrangements within the genome.
Results: We performed array comparative genomic hybridization in 29 primary tumors from high risk patients with
breast cancer. The specimens were flow sorted according to ploidy to increase tumor cell purity prior to array CGH.
We describe the number of chromosomal breaks as well as the patterns of breaks on individual chromosomes in
each tumor. There were differences in chromosomal breakage patterns between the 3 clinical subtypes of breast
cancers, although the highest density of breaks occurred at chromosome 17 in all subtypes, suggesting a particular
proclivity of this chromosome for breaks. We also observed chromothripsis affecting various chromosomes in 41%
of high risk breast cancers.
Conclusions: Our results provide a new insight into the genomic complexity of breast cancer. Genomic instability
dependent on chromosomal breakage events is not stochastic, targeting some chromosomes clearly more than
others. We report a much higher percentage of chromothripsis than described previously in other cancers and this
suggests that massive genomic rearrangements occurring in a single catastrophic event may shape many breast
cancer genomes.
Keywords: Breast cancer, Genomic instability, Array CGH, Copy number alterations, Chromosomal breakpoints,
Chromothripsis, Gene amplification
Background
Breast cancer is a heterogeneous disease showing diverse
clinical characteristics and various responses to the-
rapies. Although for clinical purposes, breast cancers
are categorized based on the expression of a few key
markers, such as the estrogen receptor (ER), the proges-
terone receptor (PR) and the human epidermal growth
factor receptor 2 (HER2) whose levels are assessed using
immunohistochemistry (IHC)-based methods [1], recent
genomic studies have uncovered much greater hetero-
geneity in breast cancers. Gene expression profiles in
particular have shown good potential to refine breast
tumors categories [2,3]. The most recent large-scale
study combining DNA copy number changes with gene
expression profiles (METABRIC) led to the identification
of 10 novel “integrative” subclasses with a different prog-
nosis according to subclass [4].
Most studies of DNA copy number changes in breast
tumors report on the potential clinical value of altered
genes within these changes, while few have focused on the
breakage events leading to the rearrangements themselves.
Indeed a closer examination of array CGH data suggests
that commonly studied amplicons such as the one con-
taining the ERBB2 oncogene (encoding for the HER2 re-
ceptor) are very heterogeneous, containing breaks not
only at the beginning and the end of the amplicons, but
also within the amplicons themselves. Genomic instability
is usually measured as the proportion of the genome that
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changes. This complexity has not been properly addressed
before.
In this study, we used array CGH data to evaluate the
number of putative chromosomal breaks underlying
gene amplification and deletion events. In order to
increase the sensitivity of this approach, we used DNA
extracted from tumor nuclei sorted according to ploidy.
This approach enabled the removal in many cases of nu-
clei originating from admixed non-neoplastic cells from
the analysis, revealing subtle amplicons and deletions, as
well as intra-amplicon and intra-deletion breaks not
previously reported. In a relatively small sample size
enriched for high-risk breast cancers, we observed fre-
quent breakpoints patterns and configurations of DNA
breaks suggestive of chromothripsis, a recently reported
phenomenon of genomic catastrophe affecting various
chromosomes [5,6]. Finally, we observed differences in
chromosomal breakage patterns between different cli-
nical breast cancer subtypes, We show that a relatively
simple approach to the analysis of genomic data (much
less detailed than sequencing) can be very informative
when used on highly purified tumor biopsies and can
provide new insights into the biology of known clinical
categories of breast cancer.
Results
Identification and flow sorting of subpopulations from
tumor specimens
Primary tumor samples were obtained from high-risk
breast cancer patients defined as at least stage 2 or
higher breast cancer and/or <50 years old. Tumor sam-
ples typically contain various proportions of tumor cells
and normal cells as well as components of stroma and
infiltrating lymphocytes. Unlike most tumor cells, these
stromal cells do not show variations in DNA content
nor DNA copy number alterations [7]. To identify and
sort pure diploid and/or aneuploid tumor subpopula-
tions, we measured DNA content in DAPI-labeled nuclei
isolated from frozen primary breast tumor specimens
[8]. Flow sorting for fractions with different ploidy values
was performed on 48 frozen tumor samples of high risk
breast tumors. 27 tumor samples (56.3% of the total)
showed clear aneuploid cell cycle profiles (Figure 1A).
Six of these tumor samples contained inadequate num-
ber of nuclei for DNA extraction and were not analyzed
further. Thus aneuploid subpopulations sorted from 21
tumors (one subpopulation per tumor) were analyzed
with array CGH. All of these DNA samples carried gen-
omic alterations, while 2N subpopulations from these
tumors either did not carry any genomic aberrations or
carried few aberrations, which localized in all cases to
sites of common copy number variations (CNVs) as per
the Toronto CNV database. Thus the 2N subpopulations
most likely represent contaminating stroma (Figure 1D).
21 tumors out of 48 (43.8%) showed diploid-like profiles
(Figure 1B and C). Diploid profiles are more difficult to
interpret since diploid sub-populations could represent
truly diploid or near-diploid tumor nuclei mixed with
nuclei originated from stromal cells, tetraploid tumors
(T) with stromal contaminants or normal stroma only.
Thirteen (13) of 21 diploid tumors had sufficient num-
bers of nuclei for DNA extraction and array CGH. Array
CGH revealed genomic aberrations in 2N and/or 4N
fractions in 8 tumors (Figure 1E and F). Samples with an
aberrant 2N fraction were considered as truly diploid or
near-diploid tumors (D). The five samples with non-
aberrant 2N and 4N fractions were thought to originate
from completely non-aberrant tumors or normal stroma
and were excluded from further analysis. Overall, in 23 of
29 analyzed samples (21 aneuploid and 2 tetraploid), we
are confident about having obtained a highly pure fraction
of cancer nuclei. In the other 6 cases (D or D/T), tumor
nuclei could be admixed with normal nuclei to a signifi-
cant extent. Table 1 summarizes all flow sorting results.
Global instability expressed as total number of breakpoints
per genome varied widely in high-grade tumors
We performed array CGH analysis using the 244 K Agilent
platform on whole genome amplified DNA isolated from
nuclei sorted according to ploidy status. Agilent’sA D M - 2
algorithm was used to identify chromosomal segments of
altered copy number in individual subpopulations from all
tumors. We used CNV calling parameters (threshold and
ADM-2 filtrations) established in our previous work to
minimized the false positive CNV calls [9]. There are
several mechanisms which could lead to genomic re-
arrangements and a change in copy number in the human
genome. They include processes related to DNA replica-
tion and recombination as well as DNA repair [10-12].
Many, although probably not all, intra-chromosomal copy
number changes seen on array CGH are associated with
DNA breakage. In order to quantify genomic breakage-
type instability with high precision, we focused on putative
DNA breakage points, rather than on the amplifications or
deletions themselves. We identified those breakage points
as the edges of segments of DNA copy number gains and
losses as well as points of abrupt DNA copy number
changes called within larger aberrations (for more detail
see the Methods section). The precision of breakpoints
assessment is determined by the resolution of an array.
The smallest aberrations we could detect with confidence
on the 244 K Agilent platform are 100 kb in genomic
length [9].
This approach allowed the quantification of genome-
wide breakage-related instability in tumors. Examples of
putative breakpoints in various tumors are shown in
Figure 2. These breakpoints are located at sites of
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viously been shown to be involved in gene fusions (e.g.
the BCAS3 gene) [6,13].
Each tumor was assigned a “breakpoint instability
index” (BPI), which is the total number of putative
breakpoints per genome. The distribution of BPIs for the
three clinical subtypes is shown in Figure 3A. There are
no significant differences between median BPI among
the 3 clinical subtypes of breast cancer, although there is
a trend towards higher BPI in the HER2 and TNBC sub-
types. While the majority of tumors in each clinical sub-
type had BPIs in the range from 25 to 300, there were
also a few outliers, that is, tumors which were much
more unstable (BPIs >300). These outliers showed many
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Figure 1 Flow sorting profiles of tumor specimens and copy number patterns associated with different tumor subpopulations. Flow
sorting profiles (A-C) and copy number patterns (genome-wide views) identified with the ADM-2 algorithm (D-F). A) Aneuploid profile of tumor
T52, B) diploid profile of tumor T221, C) diploid-like profile of tetraploid tumor T190, D) copy number pattern in 3.5 N highly aberrant fraction
from aneuploidy tumor T210 (gray) superimposed on pattern found in 2N non-aberrant fraction from the same tumor (red) showing only
common CNVs (arrows), E) copy number pattern in 2N highly aberrant fraction from diploid tumor T221 shown in green, F) copy number pattern
in 4N aberrant fraction from tetraploid tumor T190 (blue) superimposed on pattern in 2N non-aberrant fraction from the same tumor (red)
showing only common CNVs (arrows).
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number of breakpoints. The high BPI in these outliers
could reflect additional instability mechanisms, or could
in part be due to artifacts related to whole genome amp-
lification, previously described by us [9].
The extent of instability expressed as proportion of the
genome that is altered (PGA) is shown in Figure 3B.
Again, there is no significant difference in PGA between
the 3 subtypes. As expected, BPI instability correlates
well but not perfectly with the proportion of genome
Table 1 Summary of flow sorting results
FACS profile Sample description Included in thev study Excluded from the study
Aneuploid Sufficient number of aneuploidy nuclei 21
Insufficient number of nuclei 6
Diploid Diploid tumors 2
Diploid/tetraploid tumors 6
Non-aberrant tumors (or stroma only) 5
Insufficient number of nuclei (most likely only normal tissue) 8
Total 48 29 19
Total (%) 100 60.4 39.8
CCND1  BCAS3 
BCAS3 
A 
B
C 
D
MYC  PV1 
Figure 2 Examples of putative breakpoints in the areas of frequent genomic rearrangements in breast cancer. Breakpoints on
chromosome 17 (A and B), in two HER2+ genomes, cutting through gene BCAS3, which is often rearranged and fused to other genomic sequences;
specimens T111 (A) and T333 (B). A breakpoints within the CCND1 gene on chromosome 11 in ER+ tumor; specimen T147 (C). A breakpoints within
the PVT1 oncogene at the edge of the amplicon containing the MYC oncogene in a triple negative breast tumor; specimen T199 (D).E a c hp a n e l
shows data points for log 2 ratios of fluorescence between labeled tumor DNA and the differentially labeled normal human reference. Shaded areas
identify aberrations called by the ADM-2 algorithm, and the genes are indicated with blue boxes (bottom).
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were able to analyze data on PGA from the Molecular
Taxonomy of Breast Cancer International Consortium
(METABRIC) [4]. Figure 3C shows the distribution
of PGA for 610 unsorted, high risk breast tumors
(stage >2) (85 TNBC, 83 HER2+ cancers and 442
ER+tumors) from the METABRIC cohort. Overall
these results suggest that all three clinical subtypes of stage
2 breast cancers have similar levels of instability, which
varies widely form 0.0001 up to 0.5 of the proportion
of the genome that is altered.
Patterns of instability at the level of individual
chromosomes
As measures of global instability, BPI and PGA provide
similar results in our cohort. However, when breakpoint
instability is analyzed at the level of individual chromo-
somes, focusing on breakpoints reveals much additional
complexity. This is illustrated in Figure 4. If looking at
instability as the proportion of each chromosome that is
altered (Figure 4A) the pattern of instability is very dif-
ferent from that derived from the number of breakpoints
per chromosome (Figure 4B). It becomes evident that
chromosome 8 in tumor T199 is particularly aberrant/
broken (Figure 4C).
To develop a measure of chromosomal instability, which
takes into account the different sizes of the chromosomes,
we assessed the density of chromosomal breaks for each
chromosome, by normalizing the number of breaks per
100 Mb. The heat map in Figure 5 illustrates the density
of chromosomal breaks on individual chromosomes in all
tumors. Chromosomal break density was also analyzed
separately for each clinical subtype (Additional file 2:
Figure S2). Overall, diploid tumors show less breakpoints
compared to aneuploid tumors, suggesting that the degree
of breakage-related instability is associated with chro-
mosomal-scale instability (ploidy). We then classified the
chromosomes from all tumors according to the total
number of breaks (Figure 6A). The data plotted for each
clinical subtype separately is shown in Figure 6B, C, D.
Looking at all tumors together, the highest density of
breaks occurred at chromosome 17 followed by chromo-
some 8 (Figure 5). These two chromosomes also showed
the highest total number of breaks in all tumors, followed
by chromosome 19, 20, 7 and 16 (Figure 6A). We found
that the highest number of breaks occurred on chromosome
17 in all 3 subtypes (Figure 6B, C, D), suggesting a particu-
lar proclivity of this chromosome for chromosomal breaks
in breast cancers.
The chromosome with the second highest number of
breaks was chromosome 8, but only in HER2+ tumors
and in TNBCs (Figure 6B and C). On the other hand,
ER+ tumors showed relatively more breaks on chro-
mosomes 20, 19, 11 and 16 than on chromosome 8
(Figure 6D). Both, chromosomes 11 and 16 have been
shown to be aberrant in this clinical subtype [14]. TNBCs
also had frequent breaks on chromosomes 19 and 7
(Figure 6C).
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Figure 3 Chromosome-breakage genomic instability in three clinical subtypes of breast cancer. Box plot of data representing A) Genomic
instability calculated for 29 tumors as a total number of putative breakpoints per genome (BPI), B) Genomic instability calculated for 29 tumors as
proportion genome altered, C) Genomic instability in METABRIC cohort [4] expressed as proportion genome altered.
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The high purity of the flow sorted tumors allowed us to
observe chromosomal breaks with great sensitivity.
Upon further examination of the patterns of chromo-
somal instability, it became apparent that a high density
of breakpoints on a few individual chromosomes was
driving the instability index in many tumors. The most
obvious example is the HER2+ subtype, where the
tumors with the highest instability indexes displayed
many breakpoints on chromosome 17, within and be-
yond the ERBB2 amplicon. In many tumors, one or two
chromosomes contributed predominantly to the high
number of breaks. This is especially evident in the less
aberrant tumors such as T23, T199 and T190 (Figure 7).
We realized that frequently broken chromosomes show
break patterns suggestive of chromothripsis as first
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Figure 4 Chromosome-breakage instability reveals additional complexity of breast cancer genome when shown at the level of
individual chromosomes. The instability at the level of individual chromosomes is shown for two tumors with very similar BPI. If looking at
instability as proportion of chromosome altered (A) the pattern of instability is very different than that derived from the number of breakpoints
per chromosome (B). Views of array CGH data for chromosome 8 in specimen T117 and T199, with aberrations identified with ADM-2 algorithm
(shaded areas) showing that Chromosome 8 in tumor T199 is particularly aberrant/broken (C).
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rangements confined to one or two chromosomes,
sometimes just a small part of one chromosome and
the frequent alteration of a limited number (two, some-
times three) of copy number states within affected areas
and finally, the loss of heterozygosity (LOH), which, in
our case, could not be evaluated with the array CGH
platform [5]. Figure 7 and Additional file 3: Figure S3
show examples of those patterns in the genomes from
all clinical subtypes, and the data is summarized in
Table 2. The most affected chromosomes were again
chromosome 17 (55.6% of HER2+ tumors) and chromo-
some 8 (33.3% of HER2+ tumors), and in many HER2+
tumors the phenomena occurred in tandem (33.3%), af-
fecting both chromosomes 8 and 17. ER+and TN breast
cancers did not show chromothripsis on chromosome
17, and 50% of ER + tumors showed chromothripsis on
one or two chromosomes with chromosome 11 the
most affected. The frequency of chromothripsis was
relatively lower (25%) in TNBCs and usually involved
only one chromosome.
Clinical correlations
Table 3 shows clinical information about the cohort. Tu-
mors of each clinical subtype are classified according to
the BPI from the lowest (on the top) to the highest (at
the bottom). Disease-free survival and overall survival
were measured for all primary tumors. The patients had
61 months of median follow-up. They received adjuvant
therapy according to hormone status. Only two of these
patients received neoadjuvant chemotherapy and only
one received trastuzumab. The number of samples in
each subtype was relatively small and did not allow for a
statistically significant assessment of correlation between
BPI and survival of patients. In ER +tumors, however,
there appears to be an inverse correlation between BPI
and survival (Additional file 4: Figure S4). Interestingly,
three of the 4 ER +tumors with evidence of chro-
mothripsis showed early recurrence (Table 3), which is
rather unusual in ER +breast tumors [15]. We verified if
genomic instability as measured by proportion genome
altered (PGA) could have prognostic value in ER +breast
cancers from the METABRIC cohort [4]. Figure 8 shows
Figure 5 Densities of breakpoints on individual chromosomes in all tumors. Heat map showing distribution of breakpoints within
genomes. Total number of breakpoints per each chromosome was normalized to the size of the chromosome and it is expressed as numbers of
breaks per 100 Mb. Tumors are aligned from the least aberrant (top) to the most aberrant (bottom). Tumor ploidies are indicated on the left:
tumors with diploid flow sorting profiles are marked as follows: diploid tumors (D), tetraploid tumor (T), diploid or tetraploid (D/T); tumors with
aneuploid flow sorting profiles are marked with A. The color code in the tumor number column corresponds to the clinical subtype: blue = ER+;
pink = HER2+; grey = TNBC.
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http://www.biomedcentral.com/1471-2164/15/579a Kaplan-Maier plot for disease specific survival for 377
patients with ER +tumors, stage 2 or higher, which were
divided into high (n =188) and low (n =189) instability
groups based on the median of proportion genome
altered. These results suggest that the genomic insta-
bility based on copy number alterations has prognostic
value in the ER +breast cancer subtype.
Discussion
Genomic instability is a cardinal feature of solid tumors,
including breast cancers, and various forms of instability
have been described and measured [16]. The instability
as determined by the patterns of DNA amplifications
and deletions is prognostic in breast cancer [17-20] al-
though the assessment of global patterns of amplicons
A
B
C
D
Figure 6 Distribution of breakpoints between chromosomes in all tumors and in three clinical subtypes. Total number of breaks per each
individual chromosome calculated for all tumors (A) and for tumors of each clinical subtypes: HER2+ tumors (B) TNBC (C) and ER+ tumors (D).
Chromosomes are aligned from the most aberrant (left) to the least aberrant (right).
Przybytkowski et al. BMC Genomics 2014, 15:579 Page 8 of 15
http://www.biomedcentral.com/1471-2164/15/579MYC 
ERBB2 
ERBB2 
CCND1 
T199-TNBC 
T199-TNBC 
T190-TNBC 
T23-ER+ 
T61-ER+ 
T46-ER+ 
T207-HER2+ 
T333-HER2+ 
B
A 
C
D
E 
F 
G 
H 
Figure 7 Patterns of chromothripsis. A) Genome view of array CGH data form tumor T199 is shown with aberrations identified with ADM-2
algorithm (shaded areas). B-H) Views of chromosomes affected by chromothripsis from different tumors; aberrations were identified with ADM-2
algorithm (shaded areas).
Table 2 Chromosomes affected by chromothripsis in all tumors
Tumor Instability index (BPI) Clinical type Chr. 6 Chr. 7 Chr. 8 Chr. 9 Chr. 11 Chr. 17 Chr. 19 Chr. 21 Total per tumor
T 61 30 ER+ x x 2
T 23 69 ER+ x 1
T 46 139 ER+ x x 2
T 147 434 ER+ x 1
T 190 35 TNBC x 1
T 199 93 TNBC x 1
T 79 104 TNBC x 1
T 333 64 HER2+ x x x 3
T 111 141 HER2+ x x 2
T 207 162 HER2+ x 1
T 74 215 HER2+ x x x 3
T 64 329 HER2+ x x 2
Total number per all tumors 2 2 5 1 2512
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data observed by array CGH. We have described a novel
approach for a global analysis of genomic rearrange-
ments in cancer cells, breakpoint analysis, which led us
to derive a relatively simple instability index (BPI) from
array CGH data, that encompasses all significant chro-
mosomal breaks at individual chromosomes within can-
cer genome. BPI instability is correlated with commonly
used measure of instability, the proportion of genome
altered and it may have a prognostic value as well. Most
importantly however, when breakpoint instability is
visualized at the level of individual chromosomes, it re-
veals additional complexity.
Using this breakpoints analysis approach, we confirmed
the variability in degrees of genomic instability within each
breast tumor subtype. Breakpoints inferred from array
Table 3 Summary of clinical data for all tumors
Clinical
subtype
Tumor
number
Age T N Stage Grade ER PR HER2+ Recurrence
type
DSF
(months)
OV
(months)
Last follow
(months)
BPI Chromothripsis Ploidy
ER+ 39 72 2 1 2 2 + + na Lung 126 132 25 D/T
61 61 2 1 2 2 + + - Bone 17 116 30 Yes D/T
274 61 3 3 3 na + + - Liver, bone 35 35 59 D/T
23 37 4 1 3 1 + + na Bone 57 90 69 Yes A
55 52 2 1 2 2 + + na Lung 58 66 91 A
268 71 2 na 2 2 + + - Liver, bone 45 52 121 A
46 51 3 2 3 na + - na Metastasis 23 31 139 Yes A
147 32 1 1 2 2 + + - Bone, liver 35 91 434 Yes D/T
HER2+ 333 48 2 0 2 3 - + + 18 64 Yes A
260 44 3 0 2 2 + - + 56 82 A
70 49 2 1 2 3 - + + Bone, liver 12 35 136 A
111 44 1 0 1 2 - - + Liver, lung,
bone, brain
20 39 141 Yes A
207 43 1 0 1 2 - - + 43 162 Yes A
155 58 1 1 2 3 - - + Brain, bone,
liver
26 28 187 A
74 36 2 1 2 2 + + + Bone 91 110 215 Yes A
64 70 2 2 3 3 - - + 91 329 Yes A
214 38 1 0 1 2 + + + 89 557 A
TNBC 190 72 2 0 2 2 - - - Lung,
lymph nodes
98 125 35 Yes T
253 55 2 0 2 3 - - - Abdomen,
lung, bones
71 94 74 T
117 47 3 2 3 3 - - - Skin, lung 8 26 91 A
199 44 2 0 2 2 - - - Bone 28 29 93 Yes A
79 56 1 1 2 3 - - - Bone, lung 9 29 104 Yes A
57 34 1 0 1 3 - - - 97 105 A
221 69 2 2 3 na - - - 61 122 D
25 45 2 2 3 2 - - - 127 150 A
76 43 1 0 1 3 - - - 97 152 D
52 54 2 0 2 2 - - - 85 264 A
210 45 1 1 2 2 - - - Brain, lung,
liver, bone
18 35 309 A
222 41 2 0 2 3 - - - Brain, bone,
liver
17 22 714 A
Abbreviations in the table: T tumor size category, N lymph node status (number of positive nodes), ER estrogen receptor status, PR progesterone receptor status,
HER2 HER2 receptor status, DSF disease free survival (given for the patients who relapsed), OV overall (given for the patients who died), BPI breakpoints instability
index.
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http://www.biomedcentral.com/1471-2164/15/579CGH data were previously used to assess genomic insta-
bility in combination with other measures of instability
such as a fraction of the genome altered [17]. However,
DNA analysis of non flow-sorted specimens underesti-
mates the number and longitudinal complexity of breaks
detected by array CGH. Even our approach most likely
underestimates the real number of breaks in the genome,
since every point of change in copy number may signal
many rearrangements and breaks [6] and because of the
limited coverage of the array technology we used and the
inability to detect balanced translocations. With 244 K
Agilent array we are detecting breakpoint regions of about
10 kb in size rather then specific breakpoints. Undoub-
tedly, we are missing many details, but what we see is suf-
ficient to identify the genomic signature of chromothripsis.
Chromothripsis is a complex event and what we are able
to detect with array CGH is a snapshot of a final genomic
configuration of DNA segments superimposed on the hap-
loid genome, which reflects many breakage events [21].
Thus we should consider the number of breaks described
in this study as an estimation. The spectrum of putative
breakpoints was very broad for all three clinical subtypes.
Moreover, even though most of the tumors in this study
were from high-risk patients, some tumors showed only a
few breaks and aberrations. These relatively genomically
stable tumors were either ER+or, surprisingly,TNBCs.
Many breast tumors in our cohort had numerous rear-
rangements on one or two chromosomes, while showing
fewer aberrations elsewhere. The patterns of instability on
these chromosomes were suggestive of chromothripsis.
This is the first study reporting patterns of chromothripsis
in several breast tumors. Although chromothripsis
was initially inferred from sequencing data, it could
also be identified with SNP arrays or array CGH by find-
ing regions with altered copy-number with multiple
breakpoints localized on one chromosome. Similar pat-
terns of copy-number alternations were associated with
chromothripsis in several other studies including the
original work by Stephens [6,22-25]. Interestingly, Hicks
observed what they described as “firestorms”,d e f i n e da s
clusters of “a pattern of interdigitated amplifications and
LOH” [18]. They also proposed that these events occurred
locally and often involve chromosomes 8 and 17. We
found that 12 out of 29 (41.4%) high-risk tumors show pat-
terns suggestive of chromothripsis on one or more chro-
mosomes, higher than previous reports in other cancer
types [6]. Chromothripsis might be associated with more
aggressive tumors [23,25,26], which could correspond to
our “high risk” tumors. The other reasons for such a high
prevalence of chromothripsis in our study could be the
fact that our tumor samples were enriched for cancer cells
by flow sorting of nuclei, perhaps enabling patterns of al-
tering lower amplitude copy-number changes not to be
obscured by normal DNA. Our study is the first to docu-
ment the prevalence of chromothripsis in a breast cancer
cohort, but its prevalence in larger cohort needs to be fur-
ther studied. The prevalence of chromothripsis in large co-
horts could be examined in publicly available array-based
copy number data. However, the task is not trivial consid-
ering the use of various platforms and different analytical
algorithms, as well as a lack of consistency in defining the
criteria of chromothripsis [21,27]. The bioinformatics tools
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Figure 8 Genomic instability based on copy number alterations has prognostic value in ER+ breast cancer subtype. Kaplan-Meier plot of
disease-specific survival for 344 patients from METABRIC study [4] (ER+ tumors, stage 2 or higher) divided into high and low instability groups
based on the median of proportion genome altered.
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need to be developed. Focusing on the frequency and pat-
terns of putative breaks on individual chromosomes might
be a good start.
Surprisingly, chromosome 17 shows the highest density
of breaks in all clinical subtypes. This might be related to
the unique structural features of this chromosome, such as
the relative abundance of segmental duplications and in-
terspersed repetitive elements, relatively short telomeres,
as well as its high gene content and the presence of dosage
sensitive genes [28,29]. In a large evolutionary scale the
rearrangements on this chromosome are responsible for
human diversity as well as for many hereditary disorders
[29]. Chromosome 19 was also one of the most aberrant;
similar to chromosome 17, it is very gene dense (in fact, it
is the most gene dense chromosome) and contains a high
density of repeated sequences [30]. This suggests that
genomic instability might not be equal for all chro-
mosomes and that the contribution of individual chro-
mosomes to the development of some tumors may be
determined at least in part by their structural features. The
second most aberrant chromosome in HER2+ and TNBC
tumors (but not in ER+tumors) was chromosome 8. It
has been demonstrated that aberrations on chromosome 8
correlate with p53 mutation status and overall survival in
breast tumors [31]. ER+tumors showed a relatively high
density of breaks on chromosome 11 and chromosome 16,
both of which were shown to carry recurrent aberrations
[14]. Although our small sample size precluded definitive
assessment of the effect of BPI on survival, we show in the
large METABRIC cohort that genomic instability derived
from copy number analysis may be prognostic in ER+
breast cancers. This result is with agreement with previous
studies, which showed a significant association of the ex-
tent of chromosomal instability with prognosis in ER+but
not ER- tumors [30,32,33].
Conclusion
In summary, we used a novel approach to analyze the data
obtained with flow-sorted tumor specimens using array
CGH, which provides a new insight into the genomic
complexity of breast cancer. We found that patterns of
genomic instability are different in each clinical subtype,
and that chromothripsis contributes to the instability in
many high-risk breast tumors. Chromosome 17 was the
most “broken” chromosome in all clinical subtypes. These
findings suggest that genomic instability dependent on
chromosomal breakage events is not stochastic, but oc-
curs in a stepwise fashion, targeting some chromosomes
clearly more than others. Our study supports the value of
“de-contaminating” tumor samples from stromal cells as a
way to increase the sensitivity of genomic analysis, reveal-
ing novel insights into the genomic instability patterns
underlying breast tumorigenesis.
Methods
Patients and specimens
Forty eight primary breast tumors were selected from a
large tumor bank of breast tumors obtained from pa-
tients undergoing surgery for breast cancer at the Centre
Hospitalier de l’Université de Montréal (CHUM) from
September 2001 to June 2003. These tumors were se-
lected on the basis of stage 2 or 3 at presentation and/or
age <50 and a balance between the 3 clinical subtypes.
We obtained data on clinical follow up until 2012. Pa-
tients signed informed consent for tissue banking, and
this particular study received approval from the ethics
committee of the Jewish General Hospital and the
Translational Genomics Research Institute, where the
experiments were performed. Samples were flash frozen
within an hour after surgery and stored in a −150°C
freezer until use.
This study also makes use of data generated by Molecular
Taxonomy of Breast Cancer International Consortium
(METABRIC). Cancer Research UK and the British
Columbia Cancer Agency Branch provided funding for
that project [4].
Flow sorting of nuclei
Nuclei were extracted from tissues and sorted according
to a published protocol [8]. Briefly, tumors were minced
in the presence of extraction buffer (10 mM Tris pH 7.4,
146 mM NaCl, 2 mM CaCl2, 22 mM MgCl2, BSA
0.005% and Igepal CA-630 0.1%) containing DAPI (final
concentration 10 μg/ml). The suspension was passed
through a 20 G needle to further disaggregate nuclei and
was filtered through a 40-μm mesh. Nuclei were sorted
according to DAPI intensity using an In flux cytometer
(Becton-Dickinson) with UV excitation and DAPI emis-
sion collected at >450 nm. DNA content and cell cycle
were analyzed using the software program MultiCycle
(Phoenix Flow Systems). DNA from nuclei was isolated
using QIAmp DNA MicroKit (Qiagen #56304) according
to the manufacturer’s directions for genomic DNA isola-
tion from tissues.
Whole genome amplification
We used 100 ng of both tumor and reference DNA for
each analysis. Whole genomic DNA was amplified using
GenomiPhi V2 DNA Amplification Kit (GE Healthcare
UK Limited, Buckinghamshire, UK), which uses random
primers to target the entire DNA template and φ29
DNA polymerase. The final yield of labeled genomic
DNA for hybridization on the array was 7–10 μg of both
tumor and reference DNA.
Array CGH
Copy number alterations in tumor DNA were determined
relative to the sex-matched normal human DNA (Promega,
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using microarray slides, which contain 244 000 (244 K)
oligonucleotide probes (Agilent Technologies, Santa
Clara, CA, USA). For sample preparation and hybri-
dization we followed the manufacturer’s protocol. Briefly,
amplified DNA was labeled by random priming using
either Cy5-dUTP or Cy3-dUTP. Following purification
with Microcon Centrifugation Filters, Ultracel YM-30
(Millipore, Billerica, Ma, USA). Probes were denatured
and pre-annealed with 50 μgo fh u m a nC o t - 1D N A
(Invitrogen, Burlington, Ontario, Canada). Hybridization
was performed at 65°C for 40 h with constant rotation.
After hybridization, slides were washed according to the
manufacturer’s instructions and scanned immediately with
a DNA Microarray Scanner (Agilent Technologies). Data
were extracted from scanned images using Feature Ex-
traction software, version 10.7.3.1 (Agilent). The text
files were then imported for analysis into Genomic
Workbench, standard edition 6.5.0.58 (Agilent).
Aberration detection
We used the Aberration Detection Method 2 (ADM-2)
algorithm to identify DNA copy number aberrations.
Agilent’s ADM-2 algorithm identifies all aberrant inter-
vals in a given sample with consistently high or low log
ratios based on the statistical score. It then samples adja-
cent probes to arrive at an estimation of the true range
of the aberrant segment. The statistical score represents
the deviation of the average of the log ratios from the
expected value of zero, in units of standard deviation.
The algorithm searches for intervals in which a sta-
tistical score based on the average quality weighted log
ratio of the sample and reference channels exceeds a
user specified threshold. To minimize the false positives
we used array CGH platform and CNV calling parame-
ters (threshold and filtration) previously elaborated and
reported by us [9]. This paper compared CNVs detected
by array CGH performed on whole genome amplified
DNA with those detected when array CGH was per-
formed on non- amplified DNA from MCF-7 breast can-
cer cells. Although a threshold of 6 is recommended in
the instruction manual, we used a conservative threshold
of 10 because visual inspection of the array plots led to
the rejection of several aberrations called using the lower
threshold. We applied a filtering option of minimum of
5 probes in region and minimum absolute average log2
ratio >0.3 to define aberrations. UCSC human genome
assembly hg19 was used as a reference.
Breakpoints were then identified as locations where a
change in copy number occurred as determined by
ADM-2. All putative breaks were filtered according to
a difference in the mean log2 ratio >0.5 between two
consecutive intervals. This filtration decreased the
number of breaks by 50% (±12%). When these criteria
were used, the only breakpoints found in normal diploid
fractions were associated with known germ line copy
number variations (CNV) (Figure 1). Thus our normal
diploid fractions served as a “negative control” to under-
stand the false positive rate. The fraction of the genome
altered was calculated by summing the lengths of all
regions with either amplification or deletion, as deter-
mined by ADM-2.
Additional files
Additional file 1: Figure S1. BIP instability is correlated with the
proportion of genome altered. The genomic instability derived from array
CGH data and expressed as BPI is plotted for 29 breast tumors in
function of proportion genome altered.
Additional file 2: Figure S2. Densities of breakpoints on individual
chromosomes in three clinical subtypes. A-C) Heat maps showing
distribution of breakpoints within genomes for three clinical subtypes
separately. Total number of breakpoints per each chromosome was
normalized to the size of the chromosome and it is expressed as numbers
of breaks per 100 Mb. In each panel tumors are aligned from the least
aberrant (top) to the most aberrant (bottom). Tumor ploidies are indicated
on the left: tumors with diploid flow sorting profiles are marked as follows:
diploid tumors (D), tetraploid tumor (T), diploid or tetraploid (D/T); tumors
with aneuploid flow sorting profile are marked with A. The color code in
the tumor number column corresponds to the clinical subtype: blue = ER+;
pink = HER2+; grey = TNBC.
Additional file 3: Figure S3. Patterns of chromothripsis. A-H) Views
of chromosomes affected by chromothripsis from different tumors;
aberrations were identified with ADM-2 algorithm (shaded areas).
Additional file 4: Figure S4. Patients overall survival plotted in function
of BPI. Overall survival plotted in function of BPI for patients with ER+
tumors (A) TNBC tumors (B) and HER2+ (C). The plots represent the data
from Table 3. Empty symbols stand for the surviving patients.
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